In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Business As Usual Is Not A Vision For The Future – The Value-Based Shift Is Underway

Executive Summary

Value is a concept that is increasingly embraced by providers and payers, as well as medtech manufacturers. Leading providers are organizing around value, changing their models and thereby inviting medtech manufacturers to adapt to the post fee-for-service era. Some, like Medtronic, are at the head of the game.

Advertisement

Related Content

Digital's Big Moment Has Arrived Say CEOs At Medtech Europe Panel
Value-Based Health Care: US Lags In The Global Shift To Outcomes
Mysterious Amazon/Berkshire/JPMorgan Partnership Could Disrupt Health Care, Pharma
CVS/Aetna To Merge In Defensive Play To Reshape Healthcare Delivery
Medtronic’s Deal With Aetna Heralds New Value-Based Era
US Medtech Under Trump: Below The Radar Or In The Line Of Fire?
Medtronic Takes Aim At Implantable Device Infections With TYRX Buy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV005317

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel